Quick Takeaways
- Paradigm Biocapital Advisors LP filed SCHEDULE 13G for LENZ Therapeutics, Inc. Common Stock, $0.00001 par value per share (LENZ).
- Disclosed ownership: 5.2%.
- Date of event: 20 Mar 2025.
Paradigm Biocapital Advisors LP - 20 Mar 2025 SCHEDULE 13G Report for LENZ Therapeutics, Inc. Common Stock, $0.00001 par value per share (LENZ)
- Filing Manager
- Paradigm Biocapital Advisors LP
- Reporting Manager
- Paradigm BioCapital Advisors LP
- Symbol
- LENZ
- Shares outstanding
- 27,304,462 shares
- Disclosed Ownership
- 1,419,832 shares
- Ownership
- 5.2%
- Form type
- SCHEDULE 13G
- Filing time
- 27 Mar 2025, 16:21:15 UTC
- Date of event
- 20 Mar 2025
- Next filing
- 14 Nov 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Paradigm Biocapital Advisors LP disclosed 5.2% ownership in LENZ Therapeutics, Inc. Common Stock, $0.00001 par value per share (LENZ) on 20 Mar 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 27 Mar 2025, 16:21.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (4)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Paradigm BioCapital Advisors LP | 5.2% | 1,419,832 | 1,419,832 | 0 | /s/ David K. Kim | David K. Kim / Authorized Signatory | |
| Paradigm BioCapital Advisors GP LLC | 5.2% | 1,419,832 | 1,419,832 | 0 | /s/ David K. Kim | David K. Kim / Authorized Signatory | |
| Senai Asefaw, M.D. | 5.2% | 1,419,832 | 1,419,832 | 0 | /s/ Senai Asefaw, M.D. | N/A | |
| Paradigm BioCapital International Fund Ltd. | 4.6% | 1,254,521 | 1,254,521 | 0 | /s/ David K. Kim | David K. Kim / Authorized Signatory |